| Literature DB >> 19939703 |
Shinichiro Fujii1, Shinichiro Motohashi, Kanako Shimizu, Toshinori Nakayama, Yohei Yoshiga, Masaru Taniguchi.
Abstract
Invariant natural killer T (iNKT) cells have adjuvant activity due to their ability to produce large amounts of IFN-gamma, which activates other cells in innate and acquired systems, and orchestrates protective immunity. Based on these adjuvant mechanisms, we developed iNKT cell-targeted adjuvant therapy and carried out a phase I/IIa trial on advanced lung cancer patients. The patient group with increased numbers of IFN-gamma-producing cells showed prolonged survival with a median survival time of 31.9 months. Sixty percent of the patients in this group survived for more than 2 years with only a primary treatment and without tumor progression and metastasis.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19939703 DOI： 10.1016/j.smim.2009.10.002
Source DB: PubMed Journal: Semin Immunol ISSN： 1044-5323 Impact factor: 11.130